Immunoglobulin G Antibodies to Merozoite Surface Antigens Are Associated with Recovery from Chloroquine-ResistantPlasmodium falciparumin Gambian Children
- 1 May 2006
- journal article
- Published by American Society for Microbiology in Infection and Immunity
- Vol. 74 (5), 2887-93
- https://doi.org/10.1128/iai.74.5.2887-2893.2006
Abstract
We examined the hypothesis that recovery from uncomplicated malaria in patients carrying drug-resistantPlasmodium falciparumis a measure of acquired functional immunity and may therefore be associated with humoral responses to candidate vaccine antigens. Gambian children with malaria were treated with chloroquine in 28-day trials, and recovery was defined primarily as the absence of severe clinical malaria at any time and absence of parasitemia with fever after 3 days. Plasma samples from these children were assayed by enzyme-linked immunosorbent assay for immunoglobulin G (IgG) to recombinant merozoite antigens: apical membrane antigen 1 (AMA-1) and the 19-kDa C-terminal region of merozoite surface protein 1 (MSP-119), including antigenic variants of MSP-119with double and triple substitutions. Antigen-specific IgG was more frequent in children who recovered, particularly that for MSP-119(age-adjusted odds ratios: 0.32 [95% confidence interval, 0.05, 1.87;P= 0.168] for AMA-1, 0.19 [0.03, 1.11;P= 0.019] for recombinant MSP-119, 0.24 [0.04, 1.31;P= 0.032] for the recombinant MSP-119double variant, and 0.18 [0.03, 0.97;P= 0.013] for the triple variant). IgG titers to MSP-119and to the triple variant were higher in plasma samples taken 7 days after chloroquine treatment from children who carried resistant parasites but recovered and remained parasite free. Moreover, in children who were parasitemic on day 14 or day 28, there was an age-independent relationship between parasite density and IgG to both MSP-119and the triple variant (coefficients of −0.550 and −0.590 andPvalues of 0.002 and 0.001, respectively). The results validate the use of this approach to identify antigens that are associated with protection from malaria.Keywords
This publication has 38 references indexed in Scilit:
- Human antibodies to recombinant protein constructs of Plasmodium falciparum Apical Membrane Antigen 1 (AMA1) and their associations with protection from malariaVaccine, 2004
- Combination Therapy Counteracts the Enhanced Transmission of Drug-Resistant Malaria Parasites to MosquitoesAntimicrobial Agents and Chemotherapy, 2004
- Antibody Responses toPlasmodium falciparumMerozoite Surface Protein–1 and Efficacy of Amodiaquine in Gabonese Children withP. falciparumMalariaThe Journal of Infectious Diseases, 2003
- The Human Immune Response to Plasmodium falciparum Includes Both Antibodies That Inhibit Merozoite Surface Protein 1 Secondary Processing and Blocking AntibodiesInfection and Immunity, 2002
- The economic and social burden of malariaNature, 2002
- Inhibitory and blocking monoclonal antibody epitopes on merozoite surface protein 1 of the malaria parasite Plasmodium falciparum11Edited by J. A. WellsJournal of Molecular Biology, 2001
- Clinical Immunity to Plasmodium falciparum Malaria Is Associated with Serum Antibodies to the 19-kDa C-Terminal Fragment of the Merozoite Surface Antigen, PfMSP-lThe Journal of Infectious Diseases, 1996
- A single fragment of a malaria merozoite surface protein remains on the parasite during red cell invasion and is the target of invasion-inhibiting antibodies.The Journal of Experimental Medicine, 1990
- Naturally Acquired Antibodies to Sporozoites Do Not Prevent Malaria: Vaccine Development ImplicationsScience, 1987
- Gamma-Globulin and Acquired Immunity to Human MalariaNature, 1961